Page last updated: 2024-09-03

vadimezan and npi 2358

vadimezan has been researched along with npi 2358 in 1 studies

Compound Research Comparison

Studies
(vadimezan)
Trials
(vadimezan)
Recent Studies (post-2010)
(vadimezan)
Studies
(npi 2358)
Trials
(npi 2358)
Recent Studies (post-2010) (npi 2358)
2721610136431

Protein Interaction Comparison

ProteinTaxonomyvadimezan (IC50)npi 2358 (IC50)
Tubulin alpha-1A chainSus scrofa (pig)1.8
Tubulin beta chainSus scrofa (pig)1.8
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)8.9
Mitogen-activated protein kinase 10Rattus norvegicus (Norway rat)6.8
Tubulin beta-2B chainBos taurus (cattle)2.4
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)2.4
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)2.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Castaldo, V; Colantuoni, G; Gridelli, C; Maione, P; Rossi, A; Rossi, E; Sacco, PC1

Reviews

1 review(s) available for vadimezan and npi 2358

ArticleYear
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
    The oncologist, 2009, Volume: 14, Issue:6

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diketopiperazines; Endothelial Cells; Humans; Imidazoles; Lung Neoplasms; Pericytes; Piperazines; Stilbenes; Sulfonamides; Xanthones

2009